Lumos Pharma Stock Performance
| LUMO Stock | USD 2.31 0.14 5.71% |
The company secures a Beta (Market Risk) of 0.38, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lumos Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Lumos Pharma is expected to be smaller as well. Lumos Pharma has an expected return of -0.33%. Please make sure to verify Lumos Pharma potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Lumos Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lumos Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain very healthy which may send shares a bit higher in June 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
Five Day Return (6.48) | Year To Date Return (28.26) | Ten Year Return (88.74) | All Time Return (67.37) |
Last Split Factor 1:9 | Dividend Date 2020-03-19 | Last Split Date 2020-03-19 |
1 | Disposition of 25500 shares by Pitukcheewanont Pisit Duke of Lumos Pharma at 3.3 subject to Rule 16b-3 | 03/12/2024 |
2 | Acquisition by Lalande Kevin M. of 6200 shares of Lumos Pharma at 10.0694 subject to Rule 16b-3 | 05/02/2024 |
3 | Lumos Pharma plans phase 3 trial for growth hormone drug | 05/14/2024 |
4 | LUMO Stock Earnings Lumos Pharma Misses EPS, Misses Revenue for Q1 2024 | 05/15/2024 |
5 | Lumos Pharma, Inc. Q1 2024 Earnings Call Transcript | 05/16/2024 |
6 | Were A Little Worried About Lumos Pharmas Cash Burn Rate | 05/23/2024 |
| Begin Period Cash Flow | 56 M |
Lumos |
Lumos Pharma Relative Risk vs. Return Landscape
If you would invest 300.00 in Lumos Pharma on March 1, 2024 and sell it today you would lose (69.00) from holding Lumos Pharma or give up 23.0% of portfolio value over 90 days. Lumos Pharma is currently does not generate positive expected returns and assumes 4.2886% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Lumos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lumos Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lumos Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lumos Pharma, and traders can use it to determine the average amount a Lumos Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0771
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LUMO |
Estimated Market Risk
| 4.29 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lumos Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lumos Pharma by adding Lumos Pharma to a well-diversified portfolio.
Lumos Pharma Fundamentals Growth
Lumos Stock prices reflect investors' perceptions of the future prospects and financial health of Lumos Pharma, and Lumos Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lumos Stock performance.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (12.11) % | ||||
| Current Valuation | (17.33 M) | ||||
| Shares Outstanding | 8.12 M | ||||
| Price To Earning | (2.37) X | ||||
| Price To Book | 0.78 X | ||||
| Price To Sales | 10.44 X | ||||
| Revenue | 2.05 M | ||||
| Gross Profit | 1.52 M | ||||
| EBITDA | (36.57 M) | ||||
| Net Income | (34.03 M) | ||||
| Cash And Equivalents | 79.51 M | ||||
| Cash Per Share | 9.49 X | ||||
| Total Debt | 6.58 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.59 X | ||||
| Book Value Per Share | 3.37 X | ||||
| Cash Flow From Operations | (31.09 M) | ||||
| Earnings Per Share | (4.32) X | ||||
| Market Capitalization | 18.75 M | ||||
| Total Asset | 40.64 M | ||||
| Retained Earnings | (161.52 M) | ||||
| Working Capital | 33.01 M | ||||
| Current Asset | 115.78 M | ||||
| Current Liabilities | 14.4 M | ||||
About Lumos Pharma Performance
To evaluate Lumos Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Lumos Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Lumos Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Lumos Pharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Lumos's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 54.70 | 57.43 | |
| Return On Tangible Assets | (0.84) | (0.80) | |
| Return On Capital Employed | (1.09) | (1.03) | |
| Return On Assets | (0.84) | (0.80) | |
| Return On Equity | (1.25) | (1.18) |
Things to note about Lumos Pharma performance evaluation
Checking the ongoing alerts about Lumos Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lumos Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lumos Pharma generated a negative expected return over the last 90 days | |
| Lumos Pharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.05 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 1.52 M. | |
| Lumos Pharma currently holds about 79.51 M in cash with (31.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lumos Pharma has a strong financial position based on the latest SEC filings | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Disposition of 25500 shares by Pitukcheewanont Pisit Duke of Lumos Pharma at 3.3 subject to Rule 16b-3 |
- Analyzing Lumos Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lumos Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Lumos Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lumos Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lumos Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lumos Pharma's stock. These opinions can provide insight into Lumos Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Lumos Stock analysis
When running Lumos Pharma's price analysis, check to measure Lumos Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lumos Pharma is operating at the current time. Most of Lumos Pharma's value examination focuses on studying past and present price action to predict the probability of Lumos Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lumos Pharma's price. Additionally, you may evaluate how the addition of Lumos Pharma to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Lumos Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 0.252 | Quarterly Revenue Growth 0.613 | Return On Assets (0.41) | Return On Equity (0.78) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.